DASATINIB HYDRATE

PRODUCT IDENTIFICATION

CAS NO. 302962-49-8, 863127-77-9 (hydrate)

DASATINIB

EINECS NO.  
FORMULA C22H28ClN7O3S
MOL WT. 506.02

H.S. CODE

 

TOXICITY

 

PRICE

 

SYNONYMS Sprycel;
N-(2-Chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4- yl)amino) thiazole-5-carboxamide;

CLASSIFICATION

 

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE

white to off-white powder

MELTING POINT 275 - 285 C
BOILING POINT

 

RELATIVE DENSITY  
SOLUBILITY IN WATER  
pH  
VAPOR DENSITY

 

REFRACTIVE INDEX

 

NFPA RATINGS

 

AUTOIGNITION

 

FLASH POINT

 

STABILITY Stable under normal conditions.

GENERAL DESCRIPTION & APPLICATIONS

Types of chemotherapy drug;

  • Alkylating agents
  • Angiogenesis Inhibitors
  • Anti-metabolites
  • Anti-mitotics
  • Aromatase inhibitors
  • Biologic response modifiers
  • Differentiating agents
  • Hormonal therapies
  • Monoclonal antibodies
  • Platinum derivatives
  • Signaling inhibitors
  • Topoisomerase inhibitors

Both erlotinib and gefitinib have structural motif aminoquinazoline. They functions as a specific inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase. Imatinib, a derivative of 2-phenylaminopyrimidine derivative, also act as a tyrosine kinase inhibitor. These drugs are called "signaling inhibitors" which kill cancer cells by attacking specific pathways and processes vital to the cancer cells' survival and growth to reduce side effects and increasing effectiveness. Tumors can grow only if they form new blood vessels to provide nutrients and oxygen. Some drugs can block blood vessel formation to cancer cells or the master signaling pathways that control cell growth. EGFR tyrosine kinase is overexpressed and mutated in various forms of cancers. Gefitinib or erlotinib bind to the adenosine triphosphate (ATP) in a reversible fashion in their intracellular structure and inhibits EGFR tyrosine kinase, resulting in the signal is stop by inhibiting the ATP, autophosphorylation. Tyrosine Kinase Inhibitors include;

Tyrosine Kinase Inhibitor

CAS RN.

Terreic acid

121-40-4

Damnacanthal 477-84-9
Daidzein 486-66-8
Butein 487-52-5
Cucurbitacin I 2222-07-3
3-Phenyl-1H-benzofuro(3,2-c)pyrazole 34823-86-4
Methyl 2,5-dihydroxycinnamate 63177-57-1
Nitisinone 104206-65-7
Lestaurtinib 111358-88-4
Lavendustin A 125697-92-9
Dephostatin 151606-30-3
Imatinib 152459-95-5
Erlotinib hydrochloride 183319-69-9
Erlotinib 183321-74-6
Gefitinib 184475-35-2
Semaxanib 194413-58-6
Lapatinib 231277-92-2
Ertiprotafib 251303-04-5
Sorafenib 284461-73-0
Cediranib 288383-20-0
Dasatinib 302962-49-8
Axitinib 319460-85-0
Tandutinib 387867-13-2
Vandetanib 443913-73-3
Sunitinib 557795-19-4
Pazopanib Hydrochloride 635702-64-6
Nilotinib 641571-10-0
Dasatinib hydrate 863127-77-9

Angiogenesis inhibitors or anti-angiogenic agents include bevacizumab interfere with the pro-angiogenic action of growth factors such as basic fibroblast growth factor (bFGF/FGF-2) and vascular endothelial growth factor (VEGF) that stimulates new blood vessel formation, resulting in stopping the growth of new blood vessels. Angiogenesis Inhibitors include;

Angiogenesis Inhibitor

CAS RN.

Thalidomide

50-35-1

Endostatin 187888-07-9
Vandetanib 443913-73-3
ABT 510 251579-55-2
Anecortave acetate 7753-60-8
Tetrathiomolybdate 16330-92-0
Fumagillin 23110-15-8
Omacetaxine mepesuccinate 26833-87-4
Cytochalasin E 36011-19-5
Tetra(4-N-methylpyridyl)porphine 38673-65-3
Halofuginone 55837-20-2
Interferon alfa-2a 76543-88-9
Zhengguangmycin 77108-50-0
Roquinimex 84088-42-6
Angiostatin 86090-08-6
Interferon alfa-2b 99210-65-8
5-Nitro-2-(3-phenylpropylamino)benzoic acid 107254-86-4
Thymogen 122933-59-9
O-Chloroacetylcarbamoylfumagillol 129298-91-5
Tecogalan sodium 134633-29-7
Interferon alfa-2c 142192-09-4
Squalamine 148717-90-2
Interleukin-12 187348-17-0
Cilengitide 188968-51-6
Semaxanib 194413-58-6
Bevacizumab 216974-75-3
Glufanide disodium 237068-57-4
Squalamine lactate 320725-47-1
Sunitinib malate 341031-54-7
Sunitinib 557795-19-4
Brivanib alaninate 649735-63-7

Enzyme inhibitors are molecules that combine with an enzymes in such a manner as to block the enzyme's active site and to prevent the catalytic reaction, and therefore kill a pathogen or correct a metabolic imbalance. Many enzyme inhibitors are used in the field of chemotherapy, metabolic control in pharmaceuticals as well as in the field of herbicides and pesticides. Protein kinase inhibitor is a type of enzyme inhibitor which specifically blocks the action of protein kinase. Many of protein kinase inhibitors such as imatinib and dasatinib used in the treatment of cancer are tyrosine kinase inhibitors. Protein Kinase Inhibitors include;

Protein Kinase Inhibitor

CAS RN.

Genistein

446-72-0

Emodin 518-82-1
N,N-Dimethyladenine 938-55-6
Wortmannin 19545-26-7
Adenosine-3',5'-cyclic phosphorothioate 23645-17-2
2-Naphthyl-(N-isopropyl,N-benzyl)-b-aminoethylketone hydrochloride 58753-54-1
N-(2-Aminoethyl)-5-isoquinolinesulfonamide 84468-17-7
1-(5-Isoquinolinylsulfonyl)-3-methylpiperazine 84477-73-6
Butyrolactone I 87414-49-1
N-(2-Guanidinoethyl)-5-isoquinolinesulfonamide 91742-10-8
Peptide inhibitor IP 20 99534-03-9
Fasudil 103745-39-7
1-(5-Iodonaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine 109376-83-2
Bis(amino(o-aminophenylthio)methylene)succinonitrile 109511-58-2
7-Hydroxystaurosporine 112953-11-4
3-(3-(2,5-Dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl)-1H- indol- 1-yl)propyl Carbamimidothioate 125314-64-9
9-Methoxy-9-methoxycarbonyl-8-methyl-2,3,9,10-tetrahydro- 8,11-epxoy- 1H,8H,11H-2,7b-11a- triazadibenzo(a,g) cycloocta(cde)-trinden-1-one 126643-37-6
1-(N,O-Bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl)-4-phenylpiperazine 127191-97-3
N-(2-(4-Bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide 127243-85-0
N-(2-((3-(4-Chlorophenyl)-2-propenyl)amino)ethyl)-5-isoquinoline sulfonamide 130964-43-1
N-(4-Pyridyl)-4-(1-aminoethyl)cyclohexanecarboxamide dihydrochloride 138381-45-0
2-(N-(2-Hydroxyethyl)-N-(4-methoxybenzenesulfonyl))amino- N-(4-chlorocinnamyl)- N- methyl benzylamine 139298-40-1
Alvocidib 146426-40-6
P27(Kip1) 147604-94-2
4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole 152121-30-7
Imatinib 152459-95-5
2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 154447-36-6
Temsirolimus 162635-04-3
2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 167869-21-8
Erlotinib hydrochloride 183319-69-9
Erlotinib 183321-74-6
Gefitinib 184475-35-2
Roscovitine 186692-46-6
Vatalanib 212141-54-3
Lapatinib 231277-92-2
Sorafenib 284461-73-0
Dasatinib 302962-49-8
Lapatinib ditosylate 388082-78-8
Sorafenib tosylate 475207-59-1
Sunitinib 557795-19-4
Dasatinib hydrate 863127-77-9
SALES SPECIFICATION

APPEARANCE

white to off-white powder

IDENTIFICATION

to pass

ASSAY

99.0% min

HEAVY METALS

20ppm max

RESIDUE ON IGNITION

0.2% max

WATER

4.0% max

MELTING POINT 285 - 295 C
TRANSPORTATION
PACKING
 
HAZARD CLASS  
UN NO.

 

PRICE
$2,500 (50g)